If you struggle with dark spots, hyperpigmentation or uneven skin tone, there’s a good chance La Roche-Posay’s Mela B3 line is already on your skin-care radar. Now, the brand is expanding the collection, and the one-and-only Keke Palmer is back to help tell the story.
La Roche-Posay has renewed its partnership with the actress, singer, entrepreneur and podcast host, continuing a collaboration that first launched in 2024 and quickly resonated with consumers looking for effective, inclusive solutions for discoloration. Palmer will remain the face of Mela B3 through educational campaigns, digital content and community-driven initiatives centered on skin confidence and science-backed skin care.
“Working with La Roche-Posay has been awesome,” Palmer says. “I get to have fun and lean into the humor of the fact that they are so scientific.”
The campaign kicks off this month across La Roche-Posay’s social channels, alongside an exclusive cover with PAPER Magazine that celebrates Palmer’s continued partnership with the brand.
The bigger news for your medicine cabinet: There’s a new Mela B3 product in the mix. La Roche-Posay is introducing the Mela B3 Double Dose Discoloration Treatment ($55), an intensive formula designed for the face, neck, décolleté and hands to target age spots, sun spots and dark spots while also addressing visible signs of aging.
The formula is powered by a dual-action combination of one-percent Melasyl and Proxylane. Melasyl is L’Oréal’s multi-patented pigment-correcting ingredient and the powerhouse behind the Mela B3 collection, which the brand says is clinically proven to visibly reduce a broad range of discoloration, from post-acne marks to stubborn dark spots, across all skin tones.
The science is compelling, but so is what’s driving it. When Mela B3 launched in 2024, La Roche-Posay surveyed 23,000 people and found that nearly half of respondents dealing with pigmentary disorders—conditions like melasma, solar lentigo and post-inflammatory hyperpigmentation—reported a moderate to extremely significant impact on their quality of life. The ripple effects were striking: 22 percent reported feeling viewed as dirty, 23 percent felt treated differently during administrative procedures and 21 percent said they had experienced discrimination at work.
Those numbers underscore why Palmer’s involvement feels like more than a celebrity partnership. Throughout 2026, she’ll continue showing up in dermatologist conversations, social-first content and campaign rollouts as La Roche-Posay continues working to make hyperpigmentation care more visible, inclusive and accessible.
The Mela B3 Double Dose Discoloration Treatment is available now at LaRoche-Posay.us.
